Artifical intelligence (AI) featured prominently at the 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda last week. Experts expressed excitement – and some ...

Two studies of children with HIV presented at the 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda showed that even if they are on antiretroviral therapy (ART) ...

More than half of people who received a pair of broadly neutralising antibodies (bnAbs) plus the immune-modulating drug N-803 (Anktiva) had delayed viral rebound or maintained a low or suppressed ...

Garnering a standing ovation at IAS 2025, Sameer Sah, from Medical Aid for Palestinians, provided a devastating first-hand account of what’s been happening for nearly two years in Gazan healthcare ...

Monthly oral PrEP pill advances to phase III trials Professor Kenneth Mayer at IAS 2025. ©Jacques Nkinzingabo/IAS. CC BY-SA 4.0. A once-monthly oral HIV prevention pill has shown promising results in ...

Intermittent HIV treatment schedules – such as weekends off treatment – may not be inferior to continuous treatment in adults with well-controlled HIV, but they are not suitable for adolescents with ...

Injectable treatment with long-acting cabotegravir and rilpivirine is as effective as dolutegravir-based oral treatment in adults with HIV in sub-Saharan Africa who have a history of treatment ...

One year ago, UNAIDS announced that the HIV response was at a critical crossroads. Apart from a handful of countries, the world was not on track to meet the ambitious 2030 goals: 95% of those ...

The 13th International AIDS Society Conference on HIV Science (IAS 2025) in Kigali, Rwanda has been dominated by the impact of the US government funding cuts. Especially urgent are discussions on ...

A randomised trial presented on Tuesday at the 13th International AIDS Society Conference on HIV Science (IAS 2025) showed that switching from medications thought to cause weight gain did ...

As doxycycline post-exposure prophylaxis (doxyPEP) for prevention of sexually transmitted infections (STIs) enters widespread use, questions remain about its implementation in the real world. At a ...

Killer T-cells (CD8 cells or cytotoxic T-lymphocytes) engineered to mount a rare and specific reaction to HIV-infected cells that was first seen in an experimental vaccine more than a decade ago were ...